Managing telomerase and telomere dysfunction in acral melanoma.

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Acral lentiginous melanoma (ALM) is an aggressive skin cancer subtype affecting palms, soles, and nail beds, more common in darker skin tones.
• Unlike other melanomas, ALM is not linked to UV exposure and possesses a unique genetic profile, necessitating distinct research and treatment approaches.
• Current treatments like surgery, chemotherapy, and immunotherapy show limited efficacy for ALM, emphasizing the need for novel therapeutic strategies.

Purpose of the Study:

• To review the role of telomerase in acral lentiginous melanoma development and treatment resistance.
• To explore the potential of telomerase-targeted therapies as a novel treatment strategy for ALM.
• To highlight how targeting telomerase could improve outcomes for patients with this challenging skin cancer.

Main Methods:

• Literature review focusing on telomerase activity in acral lentiginous melanoma.
• Analysis of genetic mutations, specifically in the telomerase reverse transcriptase (TERT) promoter, driving high telomerase activity in ALM.
• Evaluation of existing and emerging telomerase-targeting therapeutic approaches.

Main Results:

• Acral lentiginous melanoma exhibits high telomerase activity, often driven by TERT promoter mutations.
• This elevated telomerase activity contributes to tumor cell proliferation, immortality, and resistance to conventional therapies.
• Telomerase deregulation is a key factor in ALM tumorigenesis and therapeutic resistance.

Conclusions:

• Targeting telomerase presents a promising therapeutic avenue for acral lentiginous melanoma, particularly for patients unresponsive to standard treatments.
• Telomerase-targeted therapies hold potential as a foundational component of ALM treatment, complementing existing therapeutic modalities.
• Further research into telomerase-targeted strategies is crucial for improving outcomes in acral lentiginous melanoma patients.